TCGA-XF-AAMQ-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 71.51773982
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- INTERFERON_GAMMA_RESPONSE+0.490
- MITOTIC_SPINDLE+0.480
- G2M_CHECKPOINT+0.440
- PROTEIN_SECRETION+0.440
- TGF_BETA_SIGNALING+0.420
- E2F_TARGETS+0.390
- PI3K_AKT_MTOR_SIGNALING+0.370
- MYC_TARGETS_V1+0.360
- ALLOGRAFT_REJECTION+0.310
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- ANGIOGENESIS-0.300
- MYOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.260
- KRAS_SIGNALING_DN-0.180
- SPERMATOGENESIS-0.160
- HEDGEHOG_SIGNALING-0.130
- XENOBIOTIC_METABOLISM-0.120
- APICAL_SURFACE-0.070
- HYPOXIA-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.851 |
| 2 | BS_D7XRFE0R | Diffuse intrinsic pontine glioma | — | 0.845 |
| 3 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.840 |
| 4 | TCGA-22-5492-01A-01R-1635-07 | — | cohortSQ1 | 0.838 |
| 5 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.835 |
| 6 | SRR934830 | — | — | 0.833 |
| 7 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.832 |
| 8 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.831 |
| 9 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.829 |
| 10 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |